<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317430</url>
  </required_header>
  <id_info>
    <org_study_id>NIC2020</org_study_id>
    <nct_id>NCT04317430</nct_id>
  </id_info>
  <brief_title>Niclosamide Role in Diabetic Nephropathy</brief_title>
  <official_title>Possible Role of Niclosamide in Patients With Diabetic Kidney Disease: Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is randomized, controlled, parallel, prospective clinical study will be conducted&#xD;
      on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will&#xD;
      be recruited from Tanta University Hospital, Tanta, Egypt.&#xD;
&#xD;
      Accepted patients will be randomized into 2 groups as the following:&#xD;
&#xD;
      Control group: 30 patients will receive maximum tolerated dose of ACEI plus placebo pills for&#xD;
      six months Treatment group: 30 patients will receive maximum tolerated dose of ACEI plus&#xD;
      niclosamide tablets 1 gram once daily for six months The primary end point will be the change&#xD;
      in Urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR)&#xD;
      after six months of treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in urinary albumin creatinine ratio (UACR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>After 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary matrix metalloproteinase-7 (MMP-7) level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary podocalyxin level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Niclosamide tablets 1 gram once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide</intervention_name>
    <description>Niclosamide tablets 1 gram once daily</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>lactose tablets</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Type 2 diabetes mellitus at least 5 years ago&#xD;
&#xD;
          -  Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary&#xD;
             albumin creatinine ratio (UACR) &gt;30mg/g) despite treatment with maximum tolerated dose&#xD;
             of ACE inhibitors for at least 8 weeks prior to the screening&#xD;
&#xD;
          -  Hemoglobin A1c &gt; 6.5 % with regular use of insulin and/or oral glucose lowering agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Severe renal impairment (eGFR&lt; 30 mL/min/1.73 m2 at screening)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Chronic heart failure&#xD;
&#xD;
          -  Inflammatory or autoimmune disease&#xD;
&#xD;
          -  History of kidney disease other than diabetic nephropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Basma M El-fatatry</last_name>
    <phone>201094114899</phone>
    <email>basma.mahrous.clinical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Tanta University</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basma Mahrous</last_name>
      <phone>201094114899</phone>
      <email>basma.mahrous.clinical@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Basma Mahrous El-Fatatry</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Diabetes - Niclosamide - Diabetic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

